New therapeutic modalities include bispecific antibodies, VHHs (nanobodies), antibody drug conjugates (ADCs) and bispecific T-cell engagers (BiTEs). These next-generation of therapeutics offer novel modes of action, enhanced targeting, tissue penetration, and immune activation, and are therefore, reshaping the treatment landscape across oncology, immunology, and rare diseases.
These modalities offer unprecedented specificity, tissue penetration, and immune system engagement but face challenges such as structural complexity, short half-lives, and formulation sensitivity. SynBiosys® provides a robust platform to overcome these limitations. InnoCore applies its expertise in long-acting injectable (LAI) formulations to preserve bioactivity, increase bioavailability and deliver predictable, tunable release profiles for these delicate, next-generation therapies.
The therapeutic landscape is rapidly evolving with the introduction of next-generation therapeutics, which bring sophisticated mechanisms of action to tackle complex diseases.
New modalities can engage with novel targets, precisely modulate cellular pathways or recruit the immune system to tackle diseased cells. They are being used to target cells and even carry payloads of cytotoxic therapeutics directly to the area of disease, as well as assisting the imaging and diagnosis of a patient’s illness.
Despite their promise, these modalities are often delicate and difficult to formulate. Often times structurally complex, with short half-lives, meaning they are cleared from the human body rapidly, and sensitive to their environment e.g. pH, temperature, their bioactivity is affected easily. Especially due to their sensitivity, there is a significant challenge in formulating them into a patient-appropriate long-acting injectable dosage forms.
SynBiosys® addresses these limitations by providing a platform that stabilizes structurally intricate modalities, optimizes solubility, and extends pharmacokinetic performance. By protecting the molecular integrity during formulation, processing, and sustained release of these actives, InnoCore is able to formulate these complex molecules into a stable dosage form.
InnoCore’s long-acting injectable (LAI) technology, SynBiosys® can further enhance the clinical utility of next-generation therapeutics. Through tunable release profiles and precise control over delivery kinetics, SynBiosys® extends therapeutic half-lives, reduces dosing frequency, and can improve patient compliance through lower toxicity profiles, all while safeguarding the delicate molecular structure of these therapies.
The synergy between SynBiosys®’s characteristics and InnoCore’s LAI expertise creates a compelling, end-to-end solution: fragile next-generation therapeutics can be transformed into patient-friendly, clinically effective treatments. This integration empowers pharmaceutical developers to unlock the full potential of advanced modalities, translating cutting-edge science into tangible therapeutic outcomes.
"*" indicates required fields